Sector News

Here’s how Pfizer’s reorg and Mylan’s identity crisis yielded a giant generics merger

October 30, 2019
Life sciences

It took Pfizer and Mylan less than three months to finalize a deal that combines Pfizer’s established medicines business, Upjohn, with the Pittsburgh-based generics giant. And it all started with one well-timed phone call.

Last July, Pfizer decided to reorganize itself and lumped off-patent drugs into an autonomous unit. A month later, dogged by restive shareholders, Mylan started looking at ways to jump-start growth, namely potential deals. It wouldn’t be long before the two found common ground.

Mylan’s review included finding ways to expand its geographic footprint away from the under-pressure U.S. generics market, especially in the Asia-Pacific region and emerging markets. That review popped up on Pfizer’s dealmaking radar and then surfaced at an April 25 board meeting.

A week later, on May 2, Pfizer CEO Albert Bourla rang up Mylan Chairman Robert Coury to gauge his interest in buying the Upjohn established medicines franchise—and it happened to be right after that unit moved its global operations to Shanghai, a securities filing shows.

It was obvious that their stars were aligned. The two quickly signed a confidentiality agreement and exchanged due diligence information.

Some six weeks after that, on June 14, Coury and Mylan CEO Heather Bresch met up with Bourla and his CFO, Frank D’Amelio, in New York. There, in Pfizer’s home city, they ironed out a prototype for a potential merger between Mylan and the Upjohn business.

At that point, the pair was eyeing shared ownership of the combined company, split 59%-41% between Pfizer and Mylan shareholders. Under that framework, Pfizer would get $12 billion from the new company’s newly issued debt.

The terms would later change to Pfizer stockholders owning 57% of the combined company—which Coury, Bresch, Bourla and D’Amelio agreed on July 15.

Pfizer apparently had sought other partners, but during the month between those two deal talks, “there had not been any new developments with other potential strategic parties,” the SEC filing shows.

Pfizer also considered spinning Upjohn into a standalone business—without Mylan—as it had several years ago under then-CEO Ian Read. But after evaluating the opportunities for Upjohn growth, particularly in emerging markets, as well as Mylan’s own offerings and product pipeline, Pfizer and its advisers decided a Mylan deal would be the better option.

On July 26, each company’s board sanctioned the deal. They went public July 29, less than three months after Bourla made that first phone call.

For Mylan, the transaction offers an expanded geographic reach, especially in emerging markets such as China. It also gives the company a multinational drug giant’s market access and commercial expertise.

But the generics maker is also taking a risk. For one, Pfizer’s blockbuster nerve pain drug Lyrica has just lost exclusivity in the U.S. And in China, where Upjohn touts a strong presence and where 11% of the combined firm will reside, a bulk procurement scheme that slashed prices of 25 off-patent drugs is now set for a national rollout. That scheme is set to steal away a huge chunk of the company’s Lipitor business as it lost that particular tender to local generic players.

In the second quarter, when the program was only under testing in 11 major Chinese cities, Upjohn sales plummeted 20%. During a conference call with investors in July, Upjohn chief and future Mylan CEO Michael Goettler stressed that Upjohn’s footprint in China, built by Pfizer over 30 years, could help bring Mylan’s drugs to market faster, offering new growth opportunities there.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend